Byetta (Type 2 Diabetes) – Analysis and Forecasts to 2020

Publication date: January 2012

Keywords : diabete, cardiovascular disease, Gestational diabetes, retinopathy, obesity

Byetta (Type 2 Diabetes) – Analysis and Forecasts to 2020 Summary GlobalData’s pharmaceuticals report, “Byetta (Type 2 Diabetes) – Analysis and Forecasts to 2020” provides Byetta sales estimates for US, EU5 and Japan . In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2005-2020). The rep...

Search ReportLinker

The Largest Collection of Market Research Reports

» 1.2 Million Industry Reports
» 450,000 Company Profiles

» 850,000 Market Briefings
» 40,000 Country Guides

From +200,000 authoritative sources

Byetta (Type 2 Diabetes) – Analysis and Forecasts to 2020

Summary

GlobalData’s pharmaceuticals report, “Byetta (Type 2 Diabetes) – Analysis and Forecasts to 2020” provides Byetta sales estimates for US, EU5 and Japan . In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2005-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Byetta including historical sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Byetta including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2005-2020 for Byetta in the US, EU5 and Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Pathology Industry in the United Kingdom

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Introduction 5
2.1 Diabetes 5
2.2 Epidemiology 5
2.2.1 Prevalence 5
2.2.2 Mortality 7
2.3 Etiology and Risk Factors 9
2.3.1 Obesity 9
2.3.2 Sedentary Lifestyle 9
2.3.3 Family History and Genetics 9
2.3.4 Ethnicity 9
2.3.5 Old Age 9
2.4 Economic Impact of Diabetes 9
2.5 GlobalData Report Guidance 11
3 Type 2 Diabetes: Market Characterization 12
3.1 Type 2 Diabetes Market 12
3.2 Type 2 Diabetes Market Forecasts 13
3.3 Type 2 Diabetes Market: Drivers and Restraints 14
3.3.1 Drivers 14
3.3.2 Restraints 15
4 Classification of Diabetes 16
4.1 Types of Diabetes 16
4.1.1 Type 1 Diabetes 16
4.1.2 Type 2 Diabetes 16
4.1.3 Gestational Diabetes 16
4.2 Diabetes Complications 16
4.2.1 Cardiovascular Disease 16
4.2.2 Nephropathy 17
4.2.3 Neuropathy 17
4.2.4 Amputation 17
4.2.5 Retinopathy 17
5 Evolution of Anti-Diabetic Treatments 18
6 Medications 19
6.1 Insulin 19
6.2 Oral Medications 19
6.2.1 Sulfonylureas (SUR) 19
6.2.2 Biguanides (BGDs) 19
6.2.3 Alpha-Glucosidase Inhibitors (AGI) 21
6.2.4 Meglitinides 21
6.2.5 Thiozolidinediones (TZDs) 22
6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors 23
6.2.7 Oral Combination Therapy 23
6.3 Other Injectionable Medications 24
6.3.1 Pramlintide 24
6.3.2 Exenatide 24
6.4 Market Share as per Classes in Type 2 Diabetes 24
7 Byetta 25
7.1 Introduction 25
7.2 Mechanism of Action 25
7.3 Clinical Studies 25
7.3.1 Monotherapy 25
7.3.2 Combination Therapy 26
7.4 Approval History of Byetta 28
7.5 Factors Affecting Sales of Byetta 28
7.5.1 First in a New Class of Medicines 28
7.5.2 Association of Byetta with Weight Loss among Patients 28
7.5.3 Approval as a Monotherapy for First Line Treatment in the US 28
7.5.4 Byetta Becoming the Fourth Most Prescribed Drug in the US 29
7.5.5 Reporting of Acute Pancreatitis 29
7.5.6 Competition from Victoza and Januvia 29
7.5.7 Change in Labeling of Byetta 29
7.6 Drug Evaluation 29
7.6.1 Drug Risk Benefit Score 29
7.6.2 Intensity of Competition 30
7.7 Sales Forecasts 31
7.7.1 Target Patient Pool for Byetta 31
7.7.2 Dosing 31
7.7.3 Market Penetration 31
7.7.4 Annual Cost of Therapy 31
7.7.5 Sales Projections of Byetta 32
8 Diabetes Market: Appendix 41
8.1 Market Definitions 41
8.2 List of Abberiviations 41
8.3 Research Methodology 42
8.3.1 Coverage 42
8.3.2 Secondary Research 42
8.3.3 Forecasting 42
8.3.4 Number of Patients Approved to Take the Drug 42
8.3.5 Net Penetration of Drug 43
8.3.6 Net Annual Dosing 43
8.3.7 Annual Cost of Therapy 43
8.4 Drug Sales Estimates Model 43
8.5 Contact Us 43
8.6 Disclaimer 44
8.7 Sources 44

1.1 List of Tables

Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 5
Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 7
Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010 10
Table 4: Type 2 Diabetes, World, Major Marketed Drugs, 2010 12
Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III 13
Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 14
Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 15
Table 8: Diabetes Drugs Evolution 18
Table 9: Results of 24-Week Placebo Controlled Trial of Byetta as Monotherapy 26
Table 10: Results of 30-Week Placebo Controlled Trials of Byetta Used in Combination Therapy with Oral Anti-diabetic Agents 27
Table 11: Results of 16-Week Placebo Controlled Trial of Byetta Used in Combination Therapy with Oral Anti-diabetic Agents 28
Table 12: Approval of Byetta by Indication 28
Table 13: Drug Risk Benefit Score of Byetta 29
Table 14: Annual Cost of Therapy of Byetta, 2011 31
Table 15: Byetta, Type 2 Diabetes, Global, Sales Estimates ($m), 2005–2010 32
Table 16: Byetta, Type 2 Diabetes, Global, Sales Forecasts ($m), 2011–2020 32
Table 17: Byetta, Type 2 Diabetes, The US, Sales Estimates ($m), 2005–2010 33
Table 18: Byetta, Type 2 Diabetes, The US, Sales Forecasts ($m), 2011–2020 33
Table 19: Byetta, Type 2 Diabetes, The UK, Sales Estimates ($m), 2007–2010 34
Table 20: Byetta, Type 2 Diabetes, The UK, Sales Forecasts ($m), 2011–2020 34
Table 21: Byetta, Type 2 Diabetes, France, Sales Estimates ($m), 2008–2010 35
Table 22: Byetta, Type 2 Diabetes, France, Sales Forecasts ($m), 2011–2020 35
Table 23: Byetta, Type 2 Diabetes, Germany, Sales Estimates ($m), 2007–2010 36
Table 24: Byetta, Type 2 Diabetes, Germany, Sales Forecasts ($m), 2011–2020 36
Table 25: Byetta, Type 2 Diabetes, Italy, Sales Estimates ($m), 2008–2010 37
Table 26: Byetta, Type 2 Diabetes, Italy, Sales Forecasts ($m), 2011–2020 37
Table 27: Byetta, Type 2 Diabetes, Spain, Sales Estimates ($m), 2008–2010 38
Table 28: Byetta, Type 2 Diabetes, Spain, Sales Forecasts ($m), 2011–2020 38
Table 29: Byetta, Type 2 Diabetes, Japan, Sales Forecasts ($m), 2010–2020 39

List of Figures

Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010 6
Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030 6
Figure 3: Diabetes, World, Mortality, 2010 7
Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 8
Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 2010–2020 13
Figure 6: Mechanism of Action of Sulfonylurea 19
Figure 7: Mechanism of Action of Biguanide, Thiozolidinediones, Alpha-Glucosidase Inhibitors 20
Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 21
Figure 9: Mechanism of Action of Thiozolidinediones 22
Figure 10: Mechanism of Action of DPP IV Inhibitors 23
Figure 11: Type 2 Diabetes, Global, Market Share by Value, By Class (%), 2010 24
Figure 12: Byetta, Type 2 Diabetes, Global, Sales Estimates ($m), 2005-2010 32
Figure 13: Byetta, Type 2 Diabetes, The US, Sales Estimates ($m), 2005–2020 33
Figure 14: Byetta, Type 2 Diabetes, The UK, Sales Estimates ($m), 2007–2020 34
Figure 15: Byetta, Type 2 Diabetes, France, Sales Estimates ($m), 2008–2020 35
Figure 16: Byetta, Type 2 Diabetes, Germany, Sales Estimates ($m), 2007–2020 36
Figure 17: Byetta, Type 2 Diabetes, Italy, Sales Estimates ($m), 2008–2020 37
Figure 18: Byetta, Type 2 Diabetes, Spain, Sales Estimates ($m), 2008–2020 38
Figure 19: Byetta, Type 2 Diabetes, Japan, Sales Forecasts ($m), 2010-2020 39
Figure 20: Byetta, Type 2 Diabetes, Global, Sales Distribution (%), 2016 40
Figure 21: Patients Approved for the Drug 43

Endocrine, Nutritional And Metabolic Diseases in United Kingdom